Screener
ImmunityBio, Inc. IBRX Reportable Segment — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other revenues | 39 | 8 |
| Total revenue | 44,206 | 16,517 |
| Operating costs and expenses | ||
| Cost of sales | 238 | 58 |
| Research and development | 64,770 | 45,976 |
| Research and development – related parties | 3,219 | 2,258 |
| Selling, general and administrative | 44,461 | 31,977 |
| Selling, general and administrative – related parties | 1,309 | 677 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s reportable segment — cost of sales?
- ImmunityBio, Inc. (IBRX) reported reportable segment — cost of sales of $238K in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — cost of sales changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — cost of sales increased by 310.3% year-over-year, from $58K to $238K.
- What does reportable segment — cost of sales mean?
- Includes the direct costs attributable to the production of goods or services sold by the segment. This typically encompasses raw materials, direct labor, and manufacturing overhead directly linked to revenue generation.
Ask your AI about ImmunityBio, Inc.'s reportable segment — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude